MedPal AI aggregates health metrics from sources such as Apple Health and uses artificial intelligence to convert this data into actionable recommendations and timely alerts, helping users proactively manage their wellbeing. The company’s subscription-based model emphasises prevention and empowerment without offering medical advice.
The admission to AIM represents a pivotal milestone in MedPal AI’s growth, with a £16.5 million market capitalisation and £2 million raised to fuel expansion, comprising £1.64 million via a placing and a further £0.36 million via WRAP retail offer, enabling the company to enhance its AI capabilities and expand into new markets. Strategic partnerships, including Epassi Group UK-part of a platform reaching over 22 million users across Europe-will help accelerate MedPal AI’s market reach and adoption.
MedPal AI’s core mission of making health management accessible and intelligent is underpinned by strong ESG principles, empowering individuals to take control of their health, promoting preventative care, and reducing the burden on traditional healthcare systems.
Led by CEO Jason Drummond, a tech entrepreneur with a strong track record in building and listing companies, MedPal AI combines strong leadership, innovative AI capabilities, and a mission-driven approach to make health management more accessible and intelligent.
Jason Drummond, CEO of MedPal AI, said: “We are incredibly excited about MedPal AI’s listing on AIM, a pivotal moment that truly validates our vision to democratise preventative healthcare through accessible AI. This listing provides the platform to scale our innovative solutions, empowering even more users to proactively manage their wellbeing. We are confident that this is just the beginning of our journey to redefine health management globally.”
We congratulate MedPal AI on its AIM admission and look forward to seeing how its consumer-oriented AI platform shapes the future of preventive healthcare.